AURA · Aura Biosciences, Inc.

Track AURA — free

$6.54 +0.04 (+0.54%)

Russell 2000 member Rebalance outlook locked

Market Cap

$678.23M

103.70M

Volume · Oct 9 102.91K Avg daily vol (3M) 755.1K

Up next

Latest filing: 10-Q

filed Aug 11, 2026

Q1 2026 earnings call transcript

call held May 27, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$131.01M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-15.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$67.84M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+63.5%

Year over year · more shares

Price change (1Y)

+12.2%

Trailing year

Short interest

6.8%

Latest settlement · 11.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.62

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −2%

below

Price vs 50-day avg −8%

below

RSI (14) 48

neutral

MACD trend Positive

52-week position 39%

mid-range

Momentum

relative strength

Weak

1-month return −7%

trailing

6-month return −11%

trailing

YTD return +19%

this year

Relative strength −20%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

4 of 148 funds reported for Sep 30 · net +177 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.80% of float · ▲ +13.6% MoM · 11.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

148 holders — near 3-yr high, broad support

Squeeze score 75

high risk · 0–100

Fundamentals

Poor

EPS growth −1%

Y/Y

Free cash flow $-85.2M

Quant / Vol

risk profile

Very High

Volatility 57%

annualized · 1-yr

Max drawdown −33%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−2% Neutral

Price vs 50-day avg

−8% Bearish

RSI (14)

48 Neutral

MACD trend

Positive Bullish

52-week position

39% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

4 of 148 funds reported for Sep 30 · net +177 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

6.80% of float · ▲ +13.6% MoM · 11.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

148 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $7 · 39% Range high $9

vs 200-day avg -2% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Complete response rate at 3 months (intermediate-risk NMIBC patients)	69%	Q2 2026	—
Disease-free rate at 9- or 12-month assessment (evaluable NMIBC patients)	100%	Q2 2026	—
Objective response rate at 3 months (intermediate-risk NMIBC patients)	81%	Q2 2026	—
Phase 3 CoMpass trial enrollment	108	Q2 2026	—
Reduction in force	20%	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AURA Aura Biosciences, Inc. this stock	$678.23M	+19.4%	—	—	6.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$127.55B	+11.0%	+46.2%	29.3	1.9%
MRNA Moderna, Inc.	$78.65B	+568.0%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.14B	-4.2%	+20.8%	18.3	2.5%
CSLLY Csl Ltd	$60.24B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

148

% held: 92.1%
Reported: 4 of 148
Top holder: TCG Crossover Management,…

Held Float

View

Held by Funds

Fund positions

143

View

Short & Settlement

Short Interest Rising

Shares short

7.0M

Days to cover: 11.7d
Change: +846.5K sh

View

Short Volume

Short vol %

81%

As of: Oct 8, 2026

Short Total

View

Fails to Deliver

FTD shares

3.6K

Value: $26.7K
As of: Aug 31, 2026

View

Off-Exchange

Off-exchange %

37.3%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-106.2M

EPS diluted: $-1.76

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 14

View

Proposed Sales

Value

$82.3K

Shares: 12.8K
Filed: Jun 16, 2026

View

Exempt Offerings

Offering

$80.5M

Filed: Apr 6, 2021

View

Earnings & Events

Webcasts

Last webcast

May 27, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AURA	+7.7%	-6.9%	-10.8%	+3.6%	+19.4%
SPY	+1.3%	+2.1%	+9.0%	+1.5%	+13.5%
vs SPY	+6.4%	-9.1%	-19.8%	+2.1%	+5.9%

Key facts CIK 1501796 CUSIP 05153U107 13F (30d) 6 filings 6 filers Visit website Investor relations

AURA · Aura Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance